Omarigliptin: A new kind of long acting DPP-4 inhibitor / 药物评价研究
Drug Evaluation Research
; (6): 133-137, 2017.
Article
in Zh
| WPRIM
| ID: wpr-514995
Responsible library:
WPRO
ABSTRACT
Diabetes is a kind of metabolic disease characterized by hyperglycemia The oral hypoglycemic agents used currently are required to take every day,which brings inconvenience to patients.Omarigliptin is a small molecule DPP-4 (depeptidyl peptidase-4) inhibitor.The drug is developed by the Merck Co,mainly for the treatment of type two diabetes.The drug only need to be taken once a week,so as to improve the patient's compliance and adherence,thereby improving the therapeutic effect.This article introduces the information of omarigliptin from the aspects of synthesis,pharmacology,pharmacokinetics,and clinical research,which provides valuable information for pharmaceutical workers.
Full text:
1
Index:
WPRIM
Language:
Zh
Journal:
Drug Evaluation Research
Year:
2017
Type:
Article